Ellanse Formulation Choice: An Underestimated Risk Factor

"I chose Ellansé L because I wanted longer-lasting results. Now I have nodules that steroids can't fix, and I'm told removal is difficult." At FILLER REVISION, we treat Ellansé complications across all formulations, and the pattern is clear: patients with L and E type complications consistently arrive after more failed treatment attempts and face more complex extraction procedures. Understanding these formulation-specific differences is critical for both prevention and treatment planning.

In clinical practice, we have managed a substantial number of Ellanse complication cases and observed a clear trend: complications from longer-lasting formulations (L and E) are consistently more challenging to resolve than those from shorter-acting ones (S and M).

Key Insight: At FILLER REVISION, we see this pattern regularly — "the longer it lasts, the better" is many patients' instinct, but with collagen stimulators, longer duration means PCL microspheres remain in tissue longer, the body interacts with them longer, and potential risks increase accordingly. Our complication cases skew heavily toward L and E formulations.

Fundamental Differences Between the Four Formulations

PCL Microsphere Characteristics

Formulation | Duration | PCL Content | Microsphere Properties | Collagen Stimulation Period

------------- | ---------- | ------------- | ---------------------- | ---------------------------

Ellansé S | ~1 year | Lowest | Smaller, faster degradation | ~6–12 months

Ellansé M | ~2 years | Moderate | Medium size | ~12–18 months

Ellansé L | ~3 years | Higher | Larger, slower degradation | ~18–30 months

Ellansé E | ~4 years | Highest | Largest, slowest degradation | ~24–36 months

Recommended Use Versus Clinical Reality

Formulation | Manufacturer Recommendation | Clinical Reality

------------- | --------------------------- | -----------------

S | First-time users, conservative approach | Used relatively less (shorter duration)

M | Most commonly recommended | Most widely used clinically

L | Patients seeking long-term results | Heavily used in some markets

E | Special needs (not available in some markets) | Highest complication risk

How Formulation Affects Complications

Nodule Formation Risk

The longer PCL microspheres remain in tissue, the greater the chance of nodule formation. Research on polycaprolactone-based filler nodular complications has confirmed this duration-dependent risk pattern (de Melo et al., 2018):

Factor | S/M Types | L/E Types

-------- | ----------- | -----------

PCL retention time | Shorter (1–2 years) | Longer (3–4+ years)

Capsule development | Thinner | Potentially thicker and more mature

Collagen overgrowth risk | Lower | Higher

Palpable nodule incidence | Lower | Higher

Delayed inflammatory reaction | Less common | More common

Extraction Difficulty

When Ellanse removal is needed, formulation directly affects surgical complexity:

Extraction Factor | S | M | L | E

------------------ | --- | --- | --- | ---

Residual PCL volume | Low | Moderate | High | Highest

Capsule thickness | Thin | Moderate | Thick | Thickest

Tissue entanglement | Low | Moderate | High | Highest

Single-session completion rate | High | High | Moderate | Lower

Post-extraction tissue recovery | Fast | Moderate | Slow | Slowest

Key Insight: When Ellanse L or E develops complications, management is substantially more difficult than with S or M. This does not mean longer formulations are inherently bad — it means the trade-offs must be fully understood before making a choice.

Typical Complication Scenarios by Formulation

S Type: The Most Forgiving Choice

S type has the lowest PCL content and fastest degradation, making it the lowest-risk formulation:

• Nodule formation is rare and usually small

• Even if problems arise, significant improvement typically occurs within 12–18 months

• If extraction is needed, the thin capsule makes removal relatively straightforward

M Type: The Most Common Balanced Choice

M type is the most widely used formulation, with intermediate complication characteristics:

• Nodules may appear 6–12 months post-injection

• Steroid injections may help with early nodules

• Extraction is usually achievable in a single session

L Type: Risk Begins to Escalate

L type's increased PCL content and duration bring elevated management challenges:

• Nodule formation risk is higher than M type

• Thicker capsules reduce steroid and 5-FU penetration

• Extraction may require more refined ultrasound guidance

• Some cases may need staged extraction

E Type: Highest Risk

E type has the longest duration and highest PCL content, with the greatest complication risk and management difficulty:

• Highest nodule formation risk

• Capsules may be very thick and mature

• Medical treatment is usually of limited effect

• Extraction surgery is most complex

• Multiple sessions may be necessary

The Critical Role of Ultrasound Across Formulations

Ultrasound Appearance by Formulation

Formulation | Ultrasound Appearance | Clinical Significance

------------- | ---------------------- | ----------------------

S residual | Small hypoechoic area, thin capsule | Relatively easy to locate and extract

M residual | Moderate hypoechoic area, visible capsule line | Standard extraction procedure

L residual | Larger hypoechoic area, prominent capsule | Careful extraction path planning needed

E residual | Extensive hypoechoic area, thick septated capsule | May require staged management

Formulation-Specific Extraction Strategy

• Typically achievable through a single pinhole

• Direct extraction after ultrasound localization

• Single-session completion usually possible

• May require multiple entry points

• Capsule fragmentation before stepwise extraction

• Staged approach may be safer

• More intensive post-procedure ultrasound follow-up required

When Formulation Dictates Treatment Complexity: The FILLER REVISION Approach

At FILLER REVISION, we have developed formulation-specific extraction protocols because the approach that works for Ellansé S complications is insufficient for L or E types. Shorter formulations typically present thinner capsules that can be addressed through a single pinhole entry point. Longer formulations develop thicker, sometimes septated capsules with greater tissue entanglement, requiring more refined ultrasound navigation and potentially staged extraction. Our pre-operative ultrasound assessment identifies not just the nodule location but the capsule characteristics — thickness, septation, adherence to surrounding structures — which directly determines the extraction strategy. This formulation-aware approach is what allows us to achieve reliable outcomes even with the most challenging L and E type complications.

Factors to Consider Before Choosing a Formulation

For Patients

Consideration | Recommendation

-------------- | ---------------

First time using collagen stimulators | Start with S or M

History of filler complications | Avoid L and E

Duration expectations | Balance expectations with risk

Tolerance for uncertainty | Conservative patients should choose shorter formulations

Willingness for follow-up visits | Longer formulations require more diligent monitoring

For Practitioners

Consideration | Recommendation

-------------- | ---------------

Injection precision | L/E types demand higher technical standards

Complication management capability | Should have ultrasound-guided extraction capability

Patient selection | Avoid longer formulations in high-risk patients

Follow-up scheduling | Longer formulations require extended monitoring

Already Injected a Long-Acting Formulation?

If you've already tried treatment for Ellansé complications — especially L or E formulations — without success, FILLER REVISION specializes in exactly these cases. Our formulation-specific extraction protocols address the unique challenges each PCL variant presents.

For more on Ellanse removal, see Can Ellanse Be Removed?

Further reading:

• Collagen Stimulator Nodules: What to Do When 5-FU Fails

• Minimally Invasive Filler Lump Extraction Technique

About the Author

• Current Position: Director, Liusmed Clinic

• Specialties: Minimally invasive surgery, filler complication repair, ultrasound-guided extraction

• Experience: 15+ years of clinical minimally invasive surgery; over 10,000 successful cases

• Philosophy: "Ellanse formulation choice is not just about how long the results last — it is about how difficult complications will be to manage if they arise. Before deciding, make sure you understand the complete risk picture."